China Kanghui Holdings Considered A Capable Contender

China Kanghui Holdings KH has outperformed the S&P since its IPO in August (+20% vs. +3.4%) showing healthy investor interest in the Chinese orthopedics market, according to Piper Jaffray. KH separates itself from its competitors by implementing a well-assembled management team and its access to technology, and KH is expected to post an EPS CAGR of 22% from 2009-2015, driven by its new product launches and market share gains, Piper Jaffray reports. Piper Jaffray initiates with a Neutral rating and $14 price target. China Kanghui Holdings closed Friday at $12.33.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorLong IdeasNewsManagementAnalyst Ratingschina kanhui holdingsPiper Jaffray
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!